Clinical Trials Webinars

In this webinar, find out how to optimise oncology clinical trials using digital tools to accelerate decision-making.Oncology clinical trials present some of the most complex challenges across clinical research, impacting enrolment, efficiency, and access. Thankfully, our industry is afforded a unique opportunity to address these issues with the evolving regulatory landscape, the burgeoning field of digital health technologies (DHTs), and the increasing adoption of decentralised and digital trial methods.The US Food and Drug Administration (FDA)’s recent guidance on Direct-to-Patient (DTP) approaches, electronic Patient-Reported Outcomes (ePROs), and DHTs paves the way for incorporating patient-centric digital tools into trials.According to PwC, the use of DHTs in clinical trials has grown by 97 percent within the last five years, and Tufts recognises that the appetite for collecting digital endpoints has doubled every three years since 2015.As DHTs begin to help researchers define the new normal, it’s important to have the right strategy to define how you collect the right data to improve efficiency and experience. Learn how top 10 pharmaceutical companies are using a combination of DHTs, ePROs, clinical trial platforms and more, to ease oncology research and drastically reduce timelines. Key learning points- The right questions to ask your team to help define a digital strategy as part of your clinical development programme. - Why the expanded use of digital measures and biomarkers will continue to accelerate clinical development timelines.- How global pharmaceutical companies are benefiting from Medable’s novel approaches and technology to accelerate decision-making in oncology.Speaker: Musaddiq Khan – Vice President, Customer Value – Digital Outcomes & TA Strategy at Medable

Delve into the innovative journey of developing a new medicine using the Inhaled Oxytocin project as a case study. This technology was devised and initially developed at Monash University and is now entering clinical development in collaboration with GSK and philanthropic funding partners. Our guest speaker, Associate Professor Pete Lambert, from the Department of Pharmacy and Pharmaceutical Sciences at Monash University, brings over 20 years of expertise in pharmaceutical product development.KEY TOPICS:- Development pathway for new medicines- Proof of concept- Phase 2 clinical development- Running not-for-profit programs- Partnering with pharmaceuticalsSPEAKER:Pete Lambert, Pharmacy and Pharmaceutical Sciences, Monash UniversityABOUT PETE LAMBERT:Peter is a pharmaceutical scientist and programme director specialising in global health R&D. He currently leads the inhaled oxytocin project seeking to develop a novel oxytocin product to better manage postpartum haemorrhage in low resource settings.He is also a co-coordinator of the Global Health Therapeutic Program Area at Monash Institute of Pharmaceutical Sciences.Originally trained as a pharmacist, Pete has 20+ years experience in product development in the pharmaceutical industry.

Bringing together best practices in genomics, flow cytometry, biomarkers and clinical trial operations for successful CAR T-cell therapy clinical trials. This webinar emphasizes the challenges encountered and the importance of customized solutions in genomics, flow cytometry, biomarkers and clinical trial operations for successful CAR T-cell therapy clinical trials. The expert speakers will showcase the criticality of early engagement through two case studies, demonstrating how it allows for the design of tailored trials. They will then share best practices for overcoming challenges related to (1) monitoring CAR T-cells, (2) patient safety assurance and (3) assessment of therapy response. Join Cerba Research’s webinar to learn more about customized solutions for successful CAR T-cell therapy clinical trials and stay tuned for subsequent webinars and podcasts on their other CGT solutions.

This webinar aims to enhance understanding of Persistent Pulmonary Hypertension of the Newborn (PPHN), including its underlying physiology, diagnosis, and management, while emphasizing the collaborative efforts between neonatologists, paediatric intensivists and cardiologists to optimize patient care and outcomes. Our neonatologist speaker, Prof. Manuel Sánchez Luna, will discuss the importance of early recognition and therapeutic intervention in managing PPHN and key therapeutic strategies to improve outcomes and prevent mortality in the extremely severe cases. In addition, Prof. Sánchez Luna will address the utilization of non-invasive monitoring techniques, including pre- and post-ductal oxygen saturation, volumetric capnometry, and heart ultrasound, to identify PPHN and monitor response to specific therapies. By joining this session, you will also get insights from our cardiologist speaker, Prof. Maurice Beghetti, on the potential cardiac causes that may mimic PPHN in neonates and the importance of differentiating between cardiac and lung disease-induced pulmonary hypertension for appropriate treatment selection. Prof. Beghetti will also highlight different etiologies of PPHN and emphasize the importance of excluding cardiac lesions responsible for PPHN-like presentation. Target audience of this webinar: ICU Doctors in training – PICU, NICU and CICU; Cardiology doctors in training, ICU nurses, ECMO specialists, and other Allied Health Professionals. *This webinar is supported by an unrestricted educational grant from Masimo.

Join The Journal of Cardiovascular Aging for a webinar featuring Sanjiv Sam Gambhir, M.D., Ph.D. as he lectures on Stem Cell & Genomics: From Precision Medicine to Clinical Trial in Dish Time. The webinar will take place on April 8, 2024, at 9:00 AM (New York time, UTC-4).

The tumor microenvironment is a complex mix of cancer cells, immune cells, and other components that all play a part in tumor progression, metastasis, and therapy responses. Understanding the highly dynamic nature of the tumor microenvironment and the factors that influence those changes is essential for developing effective precision oncology therapies. Innovations in computational pathology and artificial intelligence, coupled with novel multiplex biomarker assays, are critical to fostering that understanding. Together, they are paving the way for scientists to better characterize the unique cancer cell populations, spatial relationships, and differences in immune responses in the tumor microenvironment.In this GEN webinar, Michael Downing, Senior Image Analysis Scientist at Ultivue, will review the state of the field and introduce Ultivue’s two core platform technologies: InSituPlex® assays, and its proprietary Spatial Image Analysis pipeline featuring UltiStacker.AI™ and UltiAnalyzer.AI™. He will also explain how these technologies work together to provide high confidence insights from tumor data for scientists developing precision cancer therapies.Topics covered in the webinar will include:How AI-supported spatial image analysis together with Ultivue’s InSituPlex assays deliver accurate and scalable insights into the biology of the tumor microenvironment.How Ultivue’s 12-plex assay verification demonstrates its readiness to provide a comprehensive view of the tumor microenvironment.A live Q&A session will follow the presentation, offering you a chance to pose questions to our expert panelist.

In the United States, public health and health care delivery have largely taken different and siloed approaches, with health care focused on the treatment of individuals and public health centered on the total population within a geographic region. Collaboration between the sectors is essential to advancing both health outcomes and equity—a lesson driven home during the COVID-19 pandemic. In a new webinar, Manatt Health will provide an in-depth look at the innovative ways California health agencies are working together to bridge the gap between public health and managed care health care delivery—and what other states can learn from the California model.

As the life sciences industry continues to evolve rapidly, clinical research organizations (CROs) and trial sites are facing new challenges and opportunities in 2024. This webinar is designed to provide industry leaders with a deep dive into the most critical clinical trial supply trends and the strategies needed to navigate these effectively.

A webinar organised by the APM Juniors’ Committee. Date: Tuesday 27 February 2024 Time: 18:00 – 19:30 Speakers: Professor Fliss Murtagh and Dr Donna Wakefield. Learning Objectives: 1) Why bother with research in palliative care, including benefits and challenges 2) Hot topics in palliative care research 3) How to progress from an idea to implementing change, and how to get involved in each level. This event is FREE to attend. Ticket holders will be sent the recording after the session. Please book your place to ensure you are on the mailing list for the joining link and the recording. The joining link will be emailed to you via the email you have registered your place with the day before the event takes place. Please remember to check your Junk Mail folders in case the invite has fallen in there. To avoid our emails falling into junk folders please make sure your IT department ‘safelist’ the following email addresses kate@munrosmith.co.uk | becki@munrosmith.co.uk. It has been noted that some email accounts are viewable in plain text only. With this in mind, we will provide the meeting ID and passcode to your joining instructions to avoid any issues with broken links.

This webinar pertains to fry shortening reduction, and how it impacts the bakery sector's savings. A significant focus will be given to food ingredients and innovations, along with food sustainability and environment.